

Prince Mahidol Award Conference

February 1, 2019




Chronic Myeloid Leukemia (CML)


- 15 20 % of all leukemias
- 1 2 cases per 100,000 per year

Average age of onset - 50 to 60 yrs of age


Median survival – 3 to 5 years








BCR-ABL As a Therapeutic Target for CML



STI571 (CGP 57148B) Imatinib mesylate GleevecTM, Glivec[®]







• There are currently 5 drugs on the market that target BCR-ABL



• There are currently 5 drugs on the market that target BCR-ABL




• There are currently 5 drugs on the market that target BCR-ABL

Survival has been significantly prolonged



CML Life Expectancy



Bower et al, J Clin Onc 34:2851-7, 2016





Since 2009 we have been working with the premise

"The improved survival in CML... is so dramatic that these new agents must be made available... As rapidly as possible throughout the whole world."





As we look to the future





Global programs impact CML education, access to diagnostics and therapy





Friday, February 1, 19

The Max Access Solution Model

A patient centered system of humanitarian access to encology

treatment

PATIENT SUPPORT

A support system around the patient



HEALTHCARE PROVIDERS

An approved network of cancer specialists

LOGISTICS & DISTRIBUTION

End to end validated supply chain



Procurement of quality targeted treatment



Max Access Solution for CML

